Global Conservation of Protein Status between Cell Lines and Xenografts

Julian Biau (1, 2) , E. Chautard (1, 2) , Franck Court (3) , Bruno Pereira (4) , Pierre Verrelle (5, 6) , Flavien Devun (5) , Leanne de Koning (5) , Marie Dutreix (6, 7)

1 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
2 CREaT - Cancer Resistance Exploring and Targeting
3 GReD - Génétique, Reproduction et Développement
4 Délégation à la Recherche Clinique et à l’Innovation
5 Institut Curie [Paris]
6 Signalisation normale et pathologique de l'embryon aux thérapies innovantes des cancers
7 UP11 - Université Paris-Sud - Paris 11

Common preclinical models for testing anticancer treatment include cultured human tumor cell lines in monolayer, and xenografts derived from these cell lines in immunodeficient mice. Our goal was to determine how similar the xenografts are compared with their original cell line and to determine whether it is possible to predict the stability of a xenograft model beforehand. We studied a selection of 89 protein markers of interest in 14 human cell cultures and respective subcutaneous xenografts using the reverse-phase protein array technology. We specifically focused on proteins and posttranslational modifications involved in DNA repair, PI3K pathway, apoptosis, tyrosine kinase signaling, stress, cell cycle, MAPK/ERK signaling, SAPK/JNK signaling, NFκB signaling, and adhesion/cytoskeleton. Using hierarchical clustering, most cell culture-xenograft pairs cluster together, suggesting a global conservation of protein signature. Particularly, Akt, NFkB, EGFR, and Vimentin showed very stable protein expression and phosphorylation levels highlighting that 4 of 10 pathways were highly correlated whatever the model. Other proteins were heterogeneously conserved depending on the cell line. Finally, cell line models with low Akt pathway activation and low levels of Vimentin gave rise to more reliable xenograft models. These results may be useful for the extrapolation of cell culture experiments to in vivo models in novel targeted drug discovery.

Domaines: Cancer

Julian Biau, E. Chautard, Franck Court, Bruno Pereira, Pierre Verrelle, et al.. Global Conservation of Protein Status between Cell Lines and Xenografts. Translational Oncology, 2016, 9 (4), pp.313-321. ⟨10.1016/j.tranon.2016.05.005⟩. ⟨hal-01643043⟩